[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes
US11401274B2 · kind B2 · utility
0Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2018 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Aug 20, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.